Small Biotech Innovation Act

Hozzl · 2025-07-02T01:51:21Z

Explore the details of House Bill 3731 Small Biotech Innovation Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

7/2/2025, 1:51 AM

Summary of Bill HR 3731

The bill titled "To amend title XI of the Social Security Act to establish a research and development-intensive small biotech manufacturer exception from the Medicare drug price negotiation program," designated as H.R. 3731 in the 119th Congress, introduced on June 4, 2025, aims to create an exception within the Medicare drug price negotiation program for small biotech manufacturers engaged in research and development activities.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 3731

Bill HR 3731 is currently in the status of Bill Introduced since June 4, 2025. Bill HR 3731 was introduced during Congress 119 and was introduced to the House on June 4, 2025. Bill HR 3731's most recent activity was Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. as of June 4, 2025

Bipartisan Support of Bill HR 3731

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 3731

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 3731

To amend title XI of the Social Security Act to establish a research and development-intensive small biotech manufacturer exception from the Medicare drug price negotiation program.